Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEN, SHARON X | 1 | 56.7% | +32.7% |
| COUGHLIN, MATTHEW P | 1 | 71.4% | +11.9% |
| REDDIG, PETER J | 1 | 58.0% | +40.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026136 | PHARMACEUTICAL FORMULATION OF CONCIZUMAB AND METHOD OF PRODUCTION THEREOF | REDDIG, PETER J | 89d overdue |
| 18523203 | ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | WEN, SHARON X | 33d |
| 18125932 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1626 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18523203 | ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | WEN, SHARON X | 1641 | §112 | Non-Final OA | 33d | Pending | Nov 29, 2023 |
| 18125932 | PYRUVATE KINASE R (PKR) ACTIVATING COMPOSITIONS | COUGHLIN, MATTHEW P | 1626 | DP | Final Rejection | — | Pending | Mar 24, 2023 |
| 18026136 | PHARMACEUTICAL FORMULATION OF CONCIZUMAB AND METHOD OF PRODUCTION THEREOF | REDDIG, PETER J | 1646 | §103 | Final Rejection | 89d overdue | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial